Tien Liang BioTech Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Min-Chung Chi

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Is Tien Liang BioTech (GTSM:4127) Using Too Much Debt?

Apr 19

Tien Liang BioTech (GTSM:4127) Is Carrying A Fair Bit Of Debt

Jan 04

AMMINISTRATORE DELEGATO

Min-Chung Chi

no data

Mandato

Min-Chung Chi serves as the President of Tien Liang Biotech Co Ltd.

Tien Liang BioTech Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Tien Liang BioTech Co., Ltd., Annual General Meeting, Jun 28, 2024

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.07 (vs NT$0.031 loss in 3Q 2023)

Now 22% overvalued after recent price rise

Now 22% overvalued

Upcoming dividend of NT$0.50 per share

Second quarter 2024 earnings released: NT$0.08 loss per share (vs NT$0.12 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: NT$0.17 (vs NT$0.14 in 1Q 2023)

Investor sentiment deteriorates as stock falls 17%

Full year 2023 earnings released: EPS: NT$39.00 (vs NT$1.30 in FY 2022)

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

Tien Liang BioTech Co., Ltd., Annual General Meeting, Jun 28, 2024

Third quarter 2023 earnings released: NT$0.03 loss per share (vs NT$0.20 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$0.12 (vs NT$0.22 in 2Q 2022)

Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021)

Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: NT$1.02 (vs NT$1.13 loss in FY 2020)

Second quarter 2021 earnings released: EPS NT$0.26 (vs NT$0.39 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.26 loss per share (vs NT$0.045 loss in 1Q 2020)

Is Tien Liang BioTech (GTSM:4127) Using Too Much Debt?

Full year 2020 earnings released: NT$1.13 loss per share (vs NT$1.02 loss in FY 2019)

New 90-day low: NT$10.55

Tien Liang BioTech (GTSM:4127) Is Carrying A Fair Bit Of Debt

Third quarter 2020 earnings released: NT$0.40 loss per share

New 90-day low: NT$10.60

New 90-day low: NT$10.80

New 90-day low - NT$11.45

First half earnings released

AMMINISTRATORE DELEGATO

Mandato